View this email in your browser
Asymptomatic Blood Donors with Zika Virus Infection in Martinique |  Probable Transfusion-Transmitted Babesiosis in Transplant Recipient  |  AABB US Hemovigilance Symposium, February 13-14, 2017  |  Science Section: What We're Reading  |  Calendar of Events
Asymptomatic Blood Donors with Zika Virus Infection in Martinique
Pierre Gallian et al. recently reported positive nucleic acid testing (NAT) results in 76 blood donations out of ~4000 (1.84%) blood donations surveyed over a 5 month period in Martinique, a French island in the Carribean region. Post donation enquiry at day 7 revealed that just under half of those that tested positive were asymptomatic.1 Pathogen reduction was implemented in Guadeloupe and La Martinique to help maintain safety and sustainability of the blood supply, starting with the dengue outbreak that occurred in 2010.2 The inactivation of the Zika virus in plasma has been published by Aubry et al., who demonstrated that for pre-inactivation samples with a viral load of 6.46 to 6.63 log TCID50/ml, viral replication was reduced to below the limit of detection after inactivation.3

Gallian P.  et al. Blood. 2016 Nov 8. doi: 10.1182/blood-2016-09-73791
[Epub ahead of print], Subscription may be required for full access
Read the Gallian P. et al. article here1

Irsch J. et al. Transfusion Medicine and Hemotherapy. 2011;38(1): 19-31. doi: 10.1159/000323937
Read the Irsch J. et al. full article here2
Aubry M. et al. Transfusion. 2016 Jan:56(1):33-40. doi: 10.1111/trf.13271

Read the Aubry M. et al. full article here
Probable Transfusion-Transmitted Babesiosis in Transplant Recipient
A 3-year-old immunocompromised patient received an orthotopic heart transplant followed by complications, including cytomegalovirus (CMV) pneumonitis, blood stream infections and rejection. Transplant rejection required plasmapheresis, and frequent blood draws which led to anemia, resulting in red blood cell transfusions over the course of 7 months. After the patient exhibited fever for 5 days, Babesia microti was identified, which was followed by 14 days of therapy resulting in undetectable parasitemia. Despite an investigation into potential contamination of blood products, the infectious donor and/or blood unit could not be identified; the heart used in the transplant was tested and eliminated as the source of Babesia infection. Babesiosis is the leading cause of transfusion-transmitted infection-related death; however, testing is limited to reference laboratories, as no commercial or FDA cleared method exists.1 Pathogen reduction has been shown to reduce Babesia microti in plasma components, and in platelet components suspended in PAS.2 Pathogen reduction technology for red blood cells is currently in development.

Kitt E. et al. Journal of Microbiology. Nov 2016. vol. 54. doi:101128/JCM.00981-16.
Read the full article here1
Read the INTERCEPT Blood System for Platelets [Package Insert]. Concord, CA: Cerus Corporation; 2016.2 

Read the INTERCEPT Blood System for Plasma [Package Insert]. Concord, CA: Cerus Corporation; 2015.2 
AABB US Hemovigilance Symposium, February 13-14, 2017
Register today to attend  the AABB US Hemovigilance Symposium where experts from the United States and around the world will discuss topics such as the state of US hemovigilance, international approaches to hemovigilance challenges, and the overall vision for the future of hemoviglance in the the US.

Register Here                   
Science Section: What We’re Reading

Prolonged Detection of Zika Virus in Secretions and Whole Blood
K Murray et al. Emerging Infectious Diseases (CDC). Jan 2017. Vol 23- 1. doi:10.3201/eid2301.161394
[Ahead of Print]
Read the Article

West Nile Could Be Deadlier Than Previously Thought
Zimmerman, B. "West Nile Could be Deadlier Than Previously Thought". Becker's Infection Control & Clinical Quality. 2016 Nov 17.
Read the Article

Source of Elizabethkingia Outbreak Eludes Investigators
Caroline, H. "Source of Elizabethkingia Outbreak Eludes Investigators". Medscape Medical News. 2016 Nov 1.

Read the Article
CDC. Recent Outbreaks. 2016 June 16.
Read the CDC Elizabethkingia Updates

Calendar of Events

SCCM (Society of Critical Care Medicine)
January 21-25, 2017 | Honolulu, HI
Additional Information

AABB US Hemovigilance Symposium
February 13-14, 2017 | Atlanta, GA
Additional Information

BMT Tandem Meetings (Center for International Blood & Marrow Transplant Research & American Society for Blood and Marrow Transplantation)
February 22-27, 2017 | Orlando, FL

Additional Information

ABC (America's Blood Centers) Spring Meeting
March 24-29, 2017 | Washington DC  
Additional Information

CSTM (Canadian Society for Transfusion Medicine)
April 20-23, 2017 | Ottowa, Canada  
Additional Information

SCA (Society of Cardiovascular Anesthesiologists)
April 22-26, 2017 | Orlando, FL  
Additional Information

ASPHO (The American Society of Pediatric Hematology/Oncology)
April 26-29, 2017 | Montreal, Canada  
Additional Information
Data for pathogen reduction of the ZIKA virus by the INTERCEPT Blood System, pathogen reduction system, have not been submitted for FDA review.

There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

CONTRAINDICATIONS: Contraindicated for preparation of plasma and platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet and plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS and PRECAUTIONS: Only INTERCEPT Processing Sets for platelets and plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet and plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl) phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLATELETS: INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.

PLASMA: Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

INTERCEPT Blood System for Red Blood Cells is in development and not available for sale.

Rx only. For full prescribing information, please see package insert.
MKT-EN 00165-17
Copyright © 2016 Cerus Corporation, All rights reserved.
Cerus, INTERCEPT Blood System and INTERCEPT are registered trademarks of Cerus Corporation.

Our mailing address is:
Cerus Corporation
1220 Concord Avenue
Concord, California 94520

Add us to your address book

unsubscribe from this list    update subscription preferences